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A complex network of interactions exists between the microbiome, the epithelium, and
immune cells that reside along the walls of the gastrointestinal tract. The intestinal
immune system has been assigned with the difficult task of discriminating between
commensal, harmless bacteria, and invading pathogens that translocate across the
epithelial monolayer. Importantly, it is trained to maintain tolerance against commensals,
and initiate protective immune responses against pathogens to secure intestinal
homeostasis. Breakdown of this fine balance between the host and its intestinal
microbiota can lead to intestinal inflammation and subsequently to development of
inflammatory bowel disease (IBD). A decade since their discovery, innate lymphoid cells
(ILCs) are now recognized as important regulators of intestinal homeostasis. ILC3s have
emerged as a critical subset in the gut. They are the most phenotypically diverse ILC
population and interact directly with numerous different cell types (haematopoietic and
non-haematopoeitic), as well as interface with the bacterial flora. In addition to their
contribution to intestinal pathogen immunity, they also mitigate against tissue damage
occurring following acute injury, by facilitating tissue repair and regeneration, a key
function in the maintenance of intestinal homeostasis. However, in chronic inflammation
the tables are turned and ILC3s may acquire a pro-inflammatory phenotype in the gut.
Chronic ILC activation can lead to persistent inflammation contributing to IBD and/or
colorectal cancer. In this review, we discuss current knowledge of group 3 ILCs and their
contributions to intestinal homeostasis and disease leading to novel therapeutic targets
and clinical approaches that may inform novel treatment strategies for immune-mediated
disorders, including IBD.
Keywords: group 3 innate lymphoid cells, symbiosis, intestinal inflammation, IBD, Crohn’s disease, ulcerative
colitis
INTRODUCTION
With more than 1013 microorganisms residing in the human gastrointestinal tract (1), our mucosal
immune system has excelled in preserving intestinal homeostasis by generating protective immune
responses against invading, harmful pathogens whilst maintaining tolerance toward commensals.
However, breakdown of this fine balance may lead to excessive immune activation, persistent
inflammation and ultimately to the development of inflammatory bowel diseases (IBD). The most
common IBD phenotypes, Crohn’s disease (CD) and ulcerative colitis (UC) are characterized by
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alternating phases of clinical relapse and remission. In CD
inflammation can occur in any part of the gastrointestinal tract,
whereas in UC inflammation is restricted to the colon (2).
Despite the increasing incidence of IBD in the Western world
(3), its complex etiology is yet to be fully understood. In general,
it is thought that IBD is caused by a dysregulated immune
response against the commensal bacterial flora in a genetically
predisposed host (4). In accordance with this notion, genome-
wide association studies (GWAS) have so far associated single
nucleotide polymorphisms (SNPs) in more than 200 genetic loci
with IBD susceptibility (5) including genes involved in bacterial
recognition, epithelial barrier integrity and immune activation
(6) highlighting the importance of microbiota-host interactions
and the role of the intestinal immune system, in particular the
innate one, in IBD pathogenesis.
Innate Lymphoid Cells—A New Recruit to
Mucosal Sentinel Duty
Defense against intestinal pathogens is multifaceted. The
intestinal epithelium comprises a physical barrier, which together
with the mucus layer and production of anti-microbial peptides
provides a containment barrier, which confines microbes in the
lumen. Cells of the innate immune compartment residing in the
lamina propria are key early warning sentinels detecting invading
pathogens through conserved pattern recognition receptors,
such as toll-like receptors. Pathogen detecting populations,
include cells of the mononuclear phagocyte system, including
macrophages and dendritic cells (DCs), which engulf and process
microbial antigens and then shape adaptive immune responses
by providing initial signals to adaptive lymphocytes to engage
potent antigen-specific T and B cell responses. Innate lymphoid
cells (ILCs) are recent additions to the innate immune cell
family (7–9). They are distributed throughout the human body in
lymphoid and non-lymphoid tissues, but are especially enriched
at the mucosal barrier surfaces (7), where they directly interact
with a number of different cell types; hematopoietic or other
(10–12). ILCs have lymphoid-like morphology, but lack any
antigen-specific receptors. Arising from a common lymphoid
progenitor and similarly to T cells, they can be further subdivided
into phenotypically and functionally distinct populations that
produce different combinations of effector cytokines to mediate
their functions (9–11). Their development depends on different
transcription factors, which are also used to help divide ILCs
into 3 main groups; group 1 ILCs that includes the well
characterized NK cells, as well as the non-cytotoxic ILC1s, group
2 ILCs or ILC2s, and finally group 3 ILCs including ILC3s and
lymphoid tissue inducer (LTi) cells. However, recently discovered
regulatory ILCs or ILCregs (13) may now represent an additional,
distinct ILC family member generating a potential new 4th group
of ILCs.
Much of the early work describing ILCs focused on their
developmental requirements and capacity for plasticity. An
early ILC progenitor (EILCP) rising form a common lymphoid
progenitor, which has lost T and B potential, gives rise to NK
cells, as well as all ILC lineages (14–16). Downstream of EILCP,
Id2 expressing common helper-like ILC precursor (CHILP)
gives rise to all ILCs, but not to NK cells (14), whereas all
ILCs (except lymphoid tissue inducer cells, LTis), arise from an
ILC precursor (ILCP) that expresses both Id2, and PLZF (17)
(Figure 1). Group 3 ILCs that represent the most diverse and
possibly best-characterized ILC populations both in humans and
mice (12), require RORγt for their development (18–20), while
the transcriptional factor aryl hydrocarbon receptor (AhR) is
essential for their maintenance (21, 22). In general, group 3
ILCs, can be further divided into CCR6+ LTi cells that may
or may not express CD4, and CCR6low/− ILC3s. Based on
whether or not CCR6low/− ILC3s express natural cytotoxicity
receptors (NCRs), they are additionally subdivided into NCR+
and NCR− ILC3s (Figure 1). Upon activation, NCR− ILC3s and
LTi cells produce mostly interleukin (IL)-17A, IL-17F and IL-22,
while NCR+ ILC3s produce mainly IL-22 (20, 23–27). Several
independent studies have provided evidence suggesting plasticity
within group 3 ILCs (28, 29). NCR− ILC3s can differentiate into
NCR+ ILC3s in the presence of increasing expression of T-bet
(30, 31), or even acquire an ILC1-like phenotype by completely
losing RORγt expression (29, 32). Similarly, ILC1-like ILC3s may
also differentiate in vivo into NCR− ILC3s in the presence of a
RORγt gradient (32, 33) (Figure 1). Given the enriched numbers
of group 3 ILCs in the gut mucosa and their role in preserving
intestinal homeostasis, additional studies are required to clarify
whether this profound, finely tuned plasticity within group 3
ILCs is a mechanism to regulate intestinal inflammation, and
whether this plasticity may also be extended to recently identified
ILCregs (13).
Although group 3 ILCs are primarily known for their role
in anti-bacterial immunity (20, 27), they emerge as key effector
cells at barrier surfaces. Recent studies describe their involvement
in several immune-mediated diseases such as psoriasis (34,
35), multiple sclerosis (36), or cancer (37, 38), improving
our understanding of these highly plastic cells in controlling
inflammation, while suggesting new ways of therapeutic immune
intervention. In this review, we focus on the role of group 3 ILCs
in the gut, during intestinal homeostasis and disease.
GROUP 3 ILCS PROMOTE
INTESTINAL PEACE
Microbiota-ILC3 Interactions—A Key
Partnership for a Finely Tuned Intestinal
Immune System
Group 3 ILCs accumulate in the gastrointestinal tract and gut-
associated lymphoid tissues in amicrobiota-independentmanner
(21, 39–41). They directly interact with the bacterial flora, as well
as with immune and non-hematopoietic cells creating a dynamic
network between the host and its resident microbiota that
favors symbiosis and preserves intestinal homeostasis (Figure 2).
An important aspect of this partnership is containment of
commensals to the lumen allowing for controlled bacterial
sampling by lamina propria mononuclear phagocytes. ILC3s
are key regulators of this process. Loss of ILC3s in the
intestine leads to diminished IL-22 production (a key cytokine
produced by ILC3s), and impaired production of antimicrobial
peptides by intestinal epithelial cells, culminating in peripheral
dissemination of Alcaligenes bacteria and systemic inflammation
that could be prevented by exogenous replacement of IL-22
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FIGURE 1 | Group 3 ILC development and heterogeneity. Group 3 ILCs
represent the most diverse ILC subset, comprising of CCR6+ LTi cells, and
ILC3s that can be further divided into NCR− and NCR+ ILC3s. Group 3 ILCs
rise from a common lymphoid progenitor that lost T, B and eventually NK cell
potential and depend on the transcriptional factor RORγt for their
development. Depending on the environmental stimulus, ILC3s produce a
variety of distinct cytokines such as IL-17, IL-22, IFNγ, and GM-CSF to
mediate their functions. Interestingly, ILC3s are highly plastic cells and as such
NCR− ILC3s can acquire NCR expression and became NCR+ ILC3s in the
presence of a T-bet gradient or loose completely RORγt expression to
differentiate into ILC1 like ILCs and vice versa.
(41). ILC3s also play a key role in shaping adaptive immunity.
Importantly, Hepworth et al. showed for the first time that
loss of RORγt+ ILCs in immunocompetent mice lead to
dysregulated adaptive immune responses against commensals,
an effect that was not mediated by known ILC3 associated
cytokines such as IL-17A, IL-22 and IL-23, but through
MHC II:TCR interactions instead (42). In particular, selective
deletion of MHC II expression on RORγt+ ILCs resulted in
enhanced antigen-specific Th17 responses against bacterial flora,
promoting spontaneous intestinal inflammation (42). Others
have also reported contribution of ILC3s in the generation
of Th17 responses against commensals (43), while antigen
presenting capacities through MHC II and expression of co-
stimulatory molecules have also been described for splenic ILC3s
using in vitro systems of T cell priming (44). Although ILC3s
can uptake, process and present antigen, they don’t express co-
stimulatory molecules and as such they can potentially result
in T cell energy. Thus, when absent there is uncontrolled T
cell activation and exaggerated T cell responses to commensals
that would otherwise be regulated. Establishing a balanced,
two-way relationship between ILC3s and T cells in the gut, T
cells have proven to be crucial for keeping ILC3 numbers and
functions in check. Absence of CD4+ T cells resulted in elevated
ILC numbers, increased IL-22 production and subsequently
enhanced secretion of anti-microbial peptides by epithelial cells
(45). Other more complex, dynamic interactions between ILC3s,
T cells and themicrobiota are important at different development
stages of the host. While ILC3s have an important role in
influencing bacterial composition at early developmental stages,
most likely to prevent unnecessary inflammatory responses, as
bacteria burden expands, CD4+ T cells accumulate to establish
tolerance using distinct mechanisms compared to their innate
counterparts, that may become quiescent (46).
Although IL-22 plays a central role regulating mucosal
immunity, the microbiota also play an important role fine-tuning
the ILC3/IL-22 axis. Segmented filamentous bacteria (SFB) are
commensal bacteria that selectively colonize the terminal ileum
of mice, a key inductive site of mucosal immunity. They play
a central role in the differentiation of Th17 cells (47, 48),
but also regulate innate IL-22 production. Mono-association
of germ free mice with SFB results in marked augmentation
of IL-22 production by intestinal ILC3s. In this system IL-
22 induced production of serum amyloid A proteins 1 and
2 from the intestinal epithelial cells, which in turn played
a key role promoting the differentiation of Th17 cells (49).
Other commensal bacteria may have an opposing role on IL-22
production, through induction of IL-25 by intestinal epithelial
cells, which suppresses IL-22 production by RORγt+ ILCs (50).
The microbiota ILC3 partnership extends its branches
to B cells too, the other major adaptive immune cell. In
2008, Tsuji et al. showed that LTi cells are essential for the
formation of isolated lymphoid follicles (ILFs) and T cell
independent generation of immunoglobulin A (IgA) by B cells
in the gut (51). Later that year, a study published in Nature
complemented these findings by showing that peptidoglycans
from Gram− bacteria activate LTi cells in the gut, which then
induce chemokine production by stromal cells resulting in
B cell recruitment and subsequently formation of ILFs (52).
Kruglov et al. showed that RORγt+ ILCs mediate both T
cell dependent and independent IgA production by B cells
through secretion of soluble lymphotoxin α (sLTα3) and
membrane-bound lymphotoxin β (LTα1β2), respectively (53).
Beneficial interactions have also been described between group
3 ILCs and mononuclear phagocytes (54). Bacterial sampling
by intestinal macrophages and DCs induces IL-1β secretion
that activates ILC3s, which in turn produce GM-CSF that feeds
back to mononuclear phagocytes to produce anti-inflammatory
mediators such as IL-10 and retinoic acid eventually leading
to Treg expansion and immune tolerance (54). Surprisingly,
Ibiza et al. showed that group 3 ILCs also interact with the
enteric nervous system in an attempt to maintain intestinal
homeostasis (55). Interestingly, it was shown that glial cells in the
lamina propria sense bacterial presence and secrete neurotrophic
factors that induce IL-22 production by ILC3s through the
neuroregulatory receptor RET (55), providing the first evidence
Frontiers in Immunology | www.frontiersin.org 3 April 2019 | Volume 10 | Article 676
Pantazi and Powell Group 3 ILCs in Gut Immunity
FIGURE 2 | Group 3 ILCs in intestinal homeostasis. Group 3 ILCs including ILC3s and LTi cells directly interact with the commensal bacteria in the lumen, the intestinal
epithelium, as well as with other immune cells and neurons in the lamina propria forming a finely tuned network that secures and maintains intestinal homeostasis.
of direct neuron involvement in innate immune regulation in
the gut.
ILC3s, Important Soldiers Fighting
Foreign Pathogens
In accordance with studies showing how group 3 ILCs directly
interact with the bacterial flora while working closely with
other hematopoietic and non-immune cells to secure and
maintain intestinal homeostasis, ILC3s have also been described
as key effector cells in immunity against pathogens. Even
prior to acquiring their official name, group 3 ILCs were
associated with protection against Proteobacteria (20). Loss
of NKp46+ RORγt+ IL-22 producing innate immune cells
is linked to increased susceptibility to Citrobacter rodentium
infection, which is a model for enteropathic E.coli infection
(20) ILC3s were especially important as early producers of IL-
22 (56). Lymphotoxin produced by RORγt expressing innate
immune cells was necessary to control C. rodentium infection as
lymphotoxin acted on the intestinal epithelium inducing CXCL1
and CXCL2 chemokine production and subsequently neutrophil
recruitment at the early stages of infection (57). Sonnenberg et al.
showed that infection with C. rodentium induced IL-23 mediated
IL-22 production by CD4+ LTi cells, and that this subset of
ILC3 was sufficient to promote immunity in immunodeficient
hosts (27). More recent studies showed that expression of the
G-protein-coupled receptor 183 (GPR183) on LTi cells is not
only essential for their migration to cryptopatches and ILFs
(58), but also required for ILC3-mediated protection against
C. rodentium infection (59). Notably, immunity to Citrobacter
is STAT3 dependent. STAT3 deficiency was associated with
impaired IL-22 production, and increased disease severity, which
could be rescued with exogenous IL-22 (60). STAT3 expression
was only required in ILC3s and T cells to induce protection (60).
One of the mechanisms of IL-22 mediated regulation of the
microbiota is through regulation of the glycosylation pattern
of epithelial cells. IL-22 and lymphotoxin expressed by ILC3s
control the expression of fucosyltransferase 2 (Fut2), which
triggers fucosylation of epithelial cells, which in turn can be
utilized as a nutrient source by luminal commensals (61). IL-
22 mediated fucosylation of the epithelium was dependent on
colonization of the GI tract with bacteria, and in a positive circuit,
fucosylation promoted colonization with symbiotic bacteria,
presumably by providing a favorable nutrient supply. Disruption
of this system resulted in loss of host-microbe mutualism
and rendered the host susceptible to Salmonella typhimurium
infection (61). In accordance with these findings, Pickard et al.
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FIGURE 3 | Group 3 ILCs during intestinal disease. In chronic inflammation group 3 ILCs seem to acquire a pro-inflammatory phenotype, thus contributing to the
development of IBD and/or colorectal cancer. However, they appear to have a beneficial role in GvHD.
showed that IL-22 induced fucosylation is mediated by ILC3s
upon activation with IL-23 produced by DCs during pathogen-
induced stress (62). In this setting, rapid fucosylation could also
improve tolerance to C. rodentium infection (62).
Klose et al. demonstrated that Tbet expressing; IFNγ
producing RORγt+ ILCs are key drivers of immunity against
Salmonella infections (30). Other work supports a role for ILC3s
in protective immunity against E. coli, or Klebsiella pneumoniae
and Toxoplasma gondi infection (63, 64). ILC3s also contribute to
host resistance to Rotavirus. ILC3 derived IL-22 synergizes with
IFNλ to minimize viral replication (65).
These studies point to an important role of group 3 ILCs in
promoting symbiosis with commensals and protection against
pathogens. ILC3s form a dynamic network of interactions with
the microbiome, other immune cells, the intestinal epithelium
and surprisingly with neuro-glial cells to secure intestinal
homeostasis (Figure 2).
GROUP 3 ILCS IN INTESTINAL DISEASE:
THE OTHER SIDE OF THE COIN
In a landmark study, Buonocore et al. showed that chronic
infection of immunodeficient mice with Helicobacter hepaticus
resulted in RORγt+ ILC3 mediated gut inflammation. ILC3s
produced high levels of IL-17 and IFNγ in response to IL-
23, thus contributing to the development of T-cell independent
inflammation (26). Similarly, ILC3s were crucial for the
development of innate mediated colitis using the anti-CD40
model of IBD (26). In support of a pathogenic role of ILC3s
in intestinal inflammation (Figure 3), Geremia et al. showed
that IL-23 responsive ILC3s were increased in the intestines of
patients with CD, where in response to IL-23 they produced
high levels of IBD-relevant cytokines such as IL-17 and IL-
22 (66). Shedding more light into the mechanisms underlying
ILC3-driven intestinal pathology, Pearson et al. showed that
ILC3s use GM-CSF to attract inflammatory monocytes on site,
whereas mobility of ILC3s in and out of cryptopatches appeared
to induce inflammation at non-inflamed sites (67). Recently,
Bauché et al. showed that Tregs were able to prevent ILC3-
induced colitis (68). In particular, latent activation gene 3
(LAG3) expressing Tregs reduced IL-1β and IL-23 production by
CX3CR1+ macrophages resulting in impaired IL-22 production
by ILC3s and therefore attenuated disease (68). Moreover,
using Tbx21−/−Rag2−/− Ulcerative Colitis (TRUC) mice, which
develop spontaneous colitis with clinical features that resemble
aspects of human UC (69), Powell et al. showed that IL-
23 and TNFα produced by CD103−CD11b+ mononuclear
phagocytes activated ILC3s to drive intestinal inflammation
through production of IL-17 (70). In particular, NCR− ILC3s,
the major ILC subset present in the colon of TRUC mice,
were potent producers of IL-17 and IL-22 in response to
IL-1α and IL-23, an effect that was more profound in the
presence of IL-6 (71). Interestingly, in vivo blockade of IL-
6 using neutralizing antibodies significantly attenuated colonic
inflammation in TRUC mice (71).
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Interestingly, group 3 ILCs have also been associated with a
pro-inflammatory, pathogenic role in cancer (Figure 3), a feared
complication of unopposed inflammation in patients with UC
(72, 73). IL-17+IL-22+ ILCs accumulate in colorectal cancer
occurring in Helicobacter hepaticus associated colorectal cancer.
ILC depletion alleviated invasive cancer in this model (74).
Importantly, IL-22, but not IL-17, was necessary for cancer
maintenance (74). In support of ILC3s having a role in promoting
colorectal cancer, Chan et al. showed that ILC3s were key drivers
of IL-23 induced tumorigenesis, however in this setting ILC3
actions were mediated by IL-17 (75).
Intestinal inflammation can also occur as a result of
graft vs. host disease (GvHD) in recipients of allogenic
hematopoietic stem cell transplants (AHSCT) as a treatment
of hematopoietic cell disorders including blood cancers
(76). Although several studies suggest that ILC3s may
contribute to intestinal inflammation promoting the
development of IBD or colorectal cancer, in GvHD they
might be beneficial (Figure 3). Hanash et al. showed that
IL-22 production by ILC3s was increased in patients
following pretransplant conditioning, whereas IL-22 levels
were reduced upon emergence of GvHD (77). Notably,
IL-22 deficiency in recipients resulted in significant
intestinal inflammation and tissue damage (77). Moreover,
Munneke et al. suggested that elevated numbers of
NCR+ ILC3s in peripheral blood of leukemia patients
following AHSCT were associated with reduced risk of
GvHD (78).
CONCLUDING REMARKS
Although they are phenotypically diverse, and exist as multiple
different subsets group 3 ILCs are probably the best-characterized
ILC lineage, and they appear to play an important role
regulating the balance betweenmaintenance and loss of intestinal
homeostasis. A decade after their discovery, ILC3s have emerged
as important regulators of inflammation at mucosal surfaces,
and in the gut in particular ILC3s form a dynamic network
of interactions with the microbiome, other immune cells, the
intestinal epithelium and enteric neurons to secure intestinal
homeostasis. However, ILC3s may also promote inflammation
leading to the development of IBD and/or colorectal cancer.
Additional work is needed to scrutinize ILC3 biology and their
contributions to intestinal disease. Targeting ILCs, their key
upstream activating mediators (e.g., IL-23, IL-1β, or IL6), their
survival factors (e.g., IL-7), or their effector cytokines (IL-22, IL-
17, and IFNγ) hold promise for treating inflammatory diseases
such as IBD.
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